DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced Pharm-Olam International (POI), a global Contract Research Organization (CRO), signed a multi-year, multi-million dollar contract standardizing on the cloud-based unified clinical research platform, DATATRAK ONE™. Already a CRO Connect Partner™ designing their own trials, Pharm-Olam licensed the use of multiple DATATRAK ONE™ products – uDesign, uIRT, uEDC and uTrain.
"Pharm-Olam continues to adopt new technologies to provide value across the clinical research process," said John Hovre, COO, at Pharm-Olam. "The expansion of our partnership positions Pharm-Olam to offer sponsors more dynamic, integrated data solutions for full service and functional outsourcing."
"I am especially proud to announce the signing of this agreement," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "POI is a long-term client committed to another five years. This partnership is a testament to the superiority of DATATRAK's technology and services delivery. We look forward to continuing to deliver the most user-friendly, powerful clinical research platform in support of Pharm-Olam's delivery of clinical trials."
Expanding research and clinical options for children with cancer